5 completed. 4 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 3 | 1 | Completed 1 |
Follow this drug Literature Review of STI-1558 trials Research Report on STI-1558
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Bioequivalence Trial of Fasting Single Oral STI-1558 Capsule in Healthy Chinese Subjects STI-1558 - COVID-19 | Phase 1 | Completed | Zhejiang ACEA Pharmaceutical Co. Ltd. | 32 | 2023-09-28 | 2023-12-13 |
| Study to Assess the Efficacy and Safety of STI-1558 in Adult Subjects With Mild or Moderate (COVID-19) STI-1558, STI-1558 placebo - COVID-19 | Phase 3 | Completed | Zhejiang ACEA Pharmaceutical Co. Ltd. | 1218 | 2023-02-08 | 2024-05-14 |
| A Study to Evaluate the Relative Bioavailability of STI-1558 and the Effect of Itraconazole and Rifampin on the Pharmacokinetics of STI-1558 STI-1558, Itraconazole, Rifampin - COVID-19 Pneumonia | Phase 1 | Completed | Zhejiang ACEA Pharmaceutical Co. Ltd. | 37 | 2023-01-04 | 2023-12-07 |
| Safety and Efficacy Study of STI-1558 in Healthy Adults and SARS-CoV-2-Positive Patients STI-1558 - SARS-CoV-2 Infection | Phase 1 | Completed | Zhejiang ACEA Pharmaceutical Co. Ltd. | 79 | 2022-09-16 | 2023-08-14 |
| Study to Assess the Safety, Tolerability and Pharmacokinetics of STI-1558 in Healthy Volunteers STI-1558, Placebo - COVID-19 | Phase 1 | Completed | Sorrento Therapeutics, Inc. | 58 | 2022-06-07 | 2023-01-30 |
COVID-19 (4)
Zhejiang ACEA Pharmaceutical Co. Ltd. (4) · Sorrento Therapeutics, Inc. (1)
China (4) · Australia (1)
Chen Jian, master (1) · Mike Royal, MD (1)